Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
11/4/2024 | Mkt Perform | JMP Securities | |
4/12/2024 | $5.00 → $11.00 | Buy → Hold | Jefferies |
11/1/2022 | $16.00 → $6.00 | Buy → Hold | Truist |
11/1/2022 | Outperform → Market Perform | Cowen | |
8/13/2021 | $34.00 | Outperform | Robert W. Baird |
8/13/2021 | $34.00 | Outperform | Baird |
4 - Instil Bio, Inc. (0001789769) (Issuer)
4 - Instil Bio, Inc. (0001789769) (Issuer)
4 - Instil Bio, Inc. (0001789769) (Issuer)
JMP Securities initiated coverage of Instil Bio with a rating of Mkt Perform
Jefferies downgraded Instil Bio from Buy to Hold and set a new price target of $11.00 from $5.00 previously
Truist downgraded Instil Bio from Buy to Hold and set a new price target of $6.00 from $16.00 previously
EFFECT - Instil Bio, Inc. (0001789769) (Filer)
S-3 - Instil Bio, Inc. (0001789769) (Filer)
10-Q - Instil Bio, Inc. (0001789769) (Filer)
SC 13G/A - Instil Bio, Inc. (0001789769) (Subject)
SC 13G/A - Instil Bio, Inc. (0001789769) (Subject)
SC 13G/A - Instil Bio, Inc. (0001789769) (Subject)
Licensed SYN-2510, a potential best-in-class PD-L1xVEGF bispecific antibody, for global ex-China development and commercialization Clinical data update for SYN-2510/IMM2510 in China from ImmuneOnco anticipated in 1H 2025 Initiation of Phase 1b/2 SYN-2510/IMM2510 + chemotherapy combination in first-line non-small cell lung cancer (NSCLC) and triple negative breast cancer (TNBC) anticipated in late 2024 and 1H 2025, respectively, by ImmuneOnco in China U.S. clinical study of SYN-2510/IMM2510 in NSCLC initiation targeted for 2H 2025 DALLAS, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil") (NASDAQ:TIL), a clinical-stage biopharmaceutical company focused on developing a
Global registrational strategy in first-line non-squamous and squamous non-small cell lung cancer (NSCLC)Global registrational strategy in first-line triple-negative breast cancer (TNBC)Initiation of Phase 1b/2 IMM2510/SYN-2510 + chemotherapy combination in first-line NSCLC anticipated in late 2024 in ChinaInitiation of Phase 1b/2 IMM2510/SYN-2510 + chemotherapy combination in first-line TNBC anticipated in early 2025 in ChinaUS IND submission for SYN-2510 targeted in late 2024, starting with Phase 2 trial of SYN-2510 monotherapy in second-line NSCLC DALLAS and SHANGHAI, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (NASDAQ:TIL, ", Instil", ))) and ImmuneOnco Biopharmaceuticals (Sh
In-licensed SYN-2510/IMM2510, a potentially best-in-class PD-L1xVEGF bispecific antibody, and SYN-27M/IMM27M, a next-generation ADCC-enhanced anti-CTLA-4 antibodyEntered into a 15-year lease for our cell therapy manufacturing facility to AstraZeneca Pharmaceuticals LP DALLAS, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil") (NASDAQ:TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its second quarter 2024 financial results and provided a corporate update. "We have expanded our pipeline with a pair of clinical-stage, potentially best-in-class therapeutics by in-licensing SYN-2510 and SYN-27M," said Bronson Crou
Shares of ASP Isotopes Inc. (NASDAQ:ASPI) fell during Friday's session after the company announced pricing of a $30 million public offering of 12 million shares at $2.50 per share. ASP Isotopes shares fell 9.2% to $3.2308 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers Vicinity Motor Corp. (NASDAQ:VEV) shares jumped 133.2% to $0.7910 after the company announced CARB certification for the VMC 1200 class 3 electric truck. Qualigen Therapeutics, Inc. (NASDAQ:QLGN) shares rose 110% to $0.4335. TOYO Co., Ltd (NASDAQ:TOYO) climbed 63.4% to $2.5322. Nisun International Enterprise Development Group Co., Ltd (NASDAQ:NISN) jumped 58% to $9.52 foll
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Instil Bio (NASDAQ:TIL) with a Buy and maintains $18 price target.
Baird analyst Jack Allen maintains Instil Bio (NASDAQ:TIL) with a Outperform and lowers the price target from $54 to $32.
Manufacturing update on voluntary pause of DELTA-1 trial of ITIL-168 in advanced melanoma expected in Q1'23 Reprioritization of resources with enrollment deferred in DELTA-2 trial of ITIL-168 First patient with non-small cell lung cancer dosed with ITIL-306, the first engineered TIL therapy using CoStAR Platform, with plans to share clinical data in 2023 Appointment of cell therapy pioneer Dr. Robert Hawkins as Head of Research and Development, and resignation of Chief Medical Officer, Dr. Zachary Roberts Company confirms cash runway into 2025 with anticipated sale-leaseback transaction of its Tarzana manufacturing facility DALLAS, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("
DALLAS, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil") (NASDAQ:TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced the appointment of Tim Moore to the role of Chief Operating Officer. Tim Moore has more than three decades of leadership experience in biopharmaceutical manufacturing and operations, including at Genentech, Kite and most recently PACT Pharma. From 2016 to 2019, Mr. Moore was Executive Vice President, Technical Operations at Kite Pharma, where he was responsible for technical operations and successfully launched Yescarta®, one of the fi